...
首页> 外文期刊>Journal of International Medical Research >Treatment of Intermittent Claudication with Antiplatelet Agents
【24h】

Treatment of Intermittent Claudication with Antiplatelet Agents

机译:抗血小板药治疗间歇性lau行

获取原文
           

摘要

In a double-blind study, 296 patients with intermittent claudication (Fontaine stage II) were treated with 250 mg ticlopidine twice daily, 500 mg aspirin every third day plus 75 mg dipyridamole three times daily, or 300 mg xanthinol nicotinate three times daily for 6 months. Ticlopidine and aspirin/dipyridamole, but not xanthinol nicotinate, improved platelet aggregation, reduced β-thromboglobulin, platelet factor IV and fibrinopeptide A concentrations, and increased antithrombin III concentrations and red blood cell filterability. No changes in lipid profiles, platelet count or fibrinogen were recorded following any treatment. The doppler systolic blood pressure ratio was improved in patients treated with ticlopidine or aspirin/dipyridamole, but not with xanthinol nicotinate. It is concluded that antiplatelet treatment is useful for the treatment of limb arteriopathy.
机译:在一项双盲研究中,对296名间歇性lau行患者(Fontaine II期)进行了每日两次250 mg噻氯匹定,每三天500 mg阿司匹林加75 mg潘生丁的每日3次或每天300次烟酸黄嘌呤的3次治疗,共6次几个月。噻氯匹定和阿司匹林/双嘧达莫,而不是烟酸黄嘌呤,改善了血小板聚集,降低了β-血球蛋白,血小板因子IV和纤维蛋白肽A的浓度,并增加了抗凝血酶III的浓度和红细胞的过滤性。任何处理后均未记录脂质分布,血小板计数或纤维蛋白原的变化。噻氯匹定或阿司匹林/双嘧达莫治疗的患者多普勒收缩压比有所改善,烟酸黄嘌呤醇则无此改善。结论是抗血小板治疗可用于治疗肢体动脉病。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号